Biointerface‐Engineered Hybrid Nanovesicles for Targeted Reprogramming of Tumor Microenvironment (Adv. Mater. 41/2024)
Hybrid Biointerface Engineering In article number 2401495, Wei Tao, Sicen Wang, Xiaoyu Xie, and co-workers present a novel biointerface-engineered hybrid nanovesicle (P-I@M1E/AAL), achieved by integrating M1-like macrophage-derived exosomes with AS1411 aptamer-conjugated liposomes. The designed P-I@M1E/AAL nanoplatform combines multiple treatment modalities, offering a promising therapeutic approach to overcome the challenges of the hypoxic and immunosuppressive tumor microenvironment. By reprogramming tumor-associated macrophages and enhancing tumor-targeted photodynamic-immunotherapy, this platform shows significant potential for improving anti-tumor treatment outcomes.
Authors
- Xueyan Zhen (ORCID: https://orcid.org/0009-0006-0611-529X)
- Wanqing Yuan
- Xiaoyu Xie (ORCID: https://orcid.org/0000-0003-3936-3565)
- Jinhai Huang (ORCID: https://orcid.org/0000-0001-9952-3175)
- Yongjiang Li (ORCID: https://orcid.org/0000-0001-6882-7862)
- Sicen Wang (ORCID: https://orcid.org/0000-0002-2757-3277)
- Tingting Zhang (ORCID: https://orcid.org/0000-0002-8227-3728)
- Min Li (ORCID: https://orcid.org/0000-0002-9428-626X)
- Wei Tao (ORCID: https://orcid.org/0000-0002-4277-3728)
- Na Kong (ORCID: https://orcid.org/0000-0002-3823-8335)
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Tibet University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Fudan University (CN)
- Xi'an Jiaotong University (CN)
Publication Details
- Journal
- Advanced Materials
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1002/adma.202470327
- Primary Topic
- Nanoplatforms for cancer theranostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00